To include your compound in the COVID-19 Resource Center, submit it here.

Actelion reports Phase II data for cenerimod in SLE

Actelion Ltd. (SIX:ATLN) reported data from a double-blind, placebo-controlled Phase II trial

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE